143 related articles for article (PubMed ID: 31657713)
1. Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case study
.
Higashimori M; Shimada H; Ichikawa K; Zhou D
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):29-36. PubMed ID: 31657713
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes.
Nagase M; Shimada H; Nii M; Ueda S; Higashimori M; Ichikawa K; Zhang L; Zhou L; Chen Y; Zhou D; Dunyak J; Al-Huniti N
J Clin Pharm Ther; 2020 Oct; 45(5):1030-1038. PubMed ID: 32227647
[TBL] [Abstract][Full Text] [Related]
3. Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.
Feng S; Cleary Y; Parrott N; Hu P; Weber C; Wang Y; Yin OQ; Shi J
Eur J Clin Pharmacol; 2015 May; 71(5):617-24. PubMed ID: 25801493
[TBL] [Abstract][Full Text] [Related]
4. Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition.
Duan P; Wu F; Moore JN; Fisher J; Crentsil V; Gonzalez D; Zhang L; Burckart GJ; Wang J
CPT Pharmacometrics Syst Pharmacol; 2019 Mar; 8(3):158-166. PubMed ID: 30520273
[TBL] [Abstract][Full Text] [Related]
5. Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype.
Kagami T; Yamade M; Suzuki T; Uotani T; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Clin Pharmacol Ther; 2018 May; 103(5):906-913. PubMed ID: 28875498
[TBL] [Abstract][Full Text] [Related]
6. Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling.
Zhou L; Sharma P; Yeo KR; Higashimori M; Xu H; Al-Huniti N; Zhou D
Eur J Pharm Sci; 2019 Nov; 139():105061. PubMed ID: 31479720
[TBL] [Abstract][Full Text] [Related]
7. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.
Barter ZE; Tucker GT; Rowland-Yeo K
Clin Pharmacokinet; 2013 Dec; 52(12):1085-100. PubMed ID: 23818090
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.
Chiang M; Sychterz C; Perera V; Merali S; Palmisano M; Templeton IE; Gaohua L
Clin Pharmacol Ther; 2023 Oct; 114(4):922-932. PubMed ID: 37467157
[TBL] [Abstract][Full Text] [Related]
9. Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.
Gong J; Iacono L; Iyer RA; Humphreys WG; Zheng M
Br J Clin Pharmacol; 2018 Jun; 84(6):1335-1345. PubMed ID: 29469197
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes.
Yang H; Yang L; Zhong X; Jiang X; Zheng L; Wang L
Eur J Pharm Sci; 2022 Oct; 177():106258. PubMed ID: 35840101
[TBL] [Abstract][Full Text] [Related]
11. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.
Lou HY; Chang CC; Sheu MT; Chen YC; Ho HO
Eur J Clin Pharmacol; 2009 Jan; 65(1):55-64. PubMed ID: 18751689
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Omeprazole Pharmacokinetics and its Inhibition on Gastric Acid Secretion in Humans Using Physiologically Based Pharmacokinetic-Pharmacodynamic Model Characterizing CYP2C19 Polymorphisms.
Li S; Xie L; Yang L; Jiang L; Yang Y; Zhi H; Liu X; Yang H; Liu L
Pharm Res; 2023 Jul; 40(7):1735-1750. PubMed ID: 37226024
[TBL] [Abstract][Full Text] [Related]
13. PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes.
Cho CK; Ko E; Mo JY; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 Jan; 47(1):82-94. PubMed ID: 38150171
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients.
Bogman K; Silkey M; Chan SP; Tomlinson B; Weber C
Eur J Clin Pharmacol; 2010 Oct; 66(10):1005-15. PubMed ID: 20549497
[TBL] [Abstract][Full Text] [Related]
15. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans.
Kobayashi K; Morita J; Chiba K; Wanibuchi A; Kimura M; Irie S; Urae A; Ishizaki T
Pharmacogenetics; 2004 Aug; 14(8):549-56. PubMed ID: 15284537
[TBL] [Abstract][Full Text] [Related]
17. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
Kagami T; Sahara S; Ichikawa H; Uotani T; Yamade M; Sugimoto M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2016 May; 43(10):1048-59. PubMed ID: 26991399
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
19. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children.
Zhou W; Johnson TN; Bui KH; Cheung SYA; Li J; Xu H; Al-Huniti N; Zhou D
Clin Pharmacol Ther; 2018 Jul; 104(1):188-200. PubMed ID: 29027194
[TBL] [Abstract][Full Text] [Related]
20. Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics.
Lenoir C; Niederer A; Rollason V; Desmeules JA; Daali Y; Samer CF
CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):30-43. PubMed ID: 34791831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
